Alexion (ALXN) and Celgene (CELG) Ratings Discusses as Revlimid Maintenance Has Last Showing Before Approval

In a Piper Jaffray research report this morning Alexion

and Celgene

are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively. Alexion has an Overweight rating with a price target of $86. Alexion closed Monday at $72.73. Celgene has an Overweight rating with a price target of $81. Celgene closed Monday at $60.96.